Loading…
The drug is currently in two Phase 2 studies.
Artelo Biosciences, Inc. (Nasdaq: ARTL) received a Notice of Allowance from the U.S. Patent and Trademark Office for its lead investigational drug. The drug is currently being evaluated in two Phase 2 studies.
The Notice of Allowance signifies that the patent application has passed examination and is allowable for patent issuance, subject to final formalities and payment of the issue fee. This development underscores the company's progress in its drug development pipeline.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.